Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Joseph R. Habib

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3445-2278; OpenAlex author ID A5052317301, A5158144381. Sources: OpenAlex.

Their work

Papers
61 (first author 10, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
180
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 5 papers · 2022: 6 papers · 2023: 5 papers · 2024: 15 papers · 2025: 18 papers · 2026: 9 papers

Papers 50 of 61

  1. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  2. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  3. Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study. Co-author DOI 10.1016/j.hpb.2026.08.011↗
  4. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Co-author DOI 10.1016/j.surg.2026.110302↗
  5. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  6. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  7. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. First author DOI 10.1097/sla.0000000000006660↗
  8. Incidental Diagnosis of Pancreatic Cancer and Association with Improved Patient Outcomes: Assessing the Potential Clinical Use of Liquid Biopsy-Based Screening… First author DOI 10.1097/xcs.0000000000001721↗
  9. Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer. Co-author DOI 10.1136/gutjnl-2025-336117↗
  10. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Co-author DOI 10.1002/advs.202417724↗
  11. Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2025.102969↗
  12. Impact of resection margin status on recurrence and survival in patients with resectable, borderline resectable, and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.surg.2024.109114↗
  13. Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration. Co-author DOI 10.1093/jnci/djaf037↗
  14. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  15. Defining the Minimal and Optimal Thresholds for Lymph Node Resection and Examination for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: A M… Co-author DOI 10.1097/sla.0000000000006295↗
  16. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  17. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735↗
  18. Transitional Subtype of Circulating Tumor Cells in Early Post-Operative Period of 5-Year Survivors Following Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006925↗
  19. Reply to: Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Addressing Statistical and Methodological Concer… Co-author DOI 10.1200/jco-24-02598↗
  20. Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… Co-author DOI 10.1245/s10434-024-16649-z↗
  21. ASO Author Reflections: Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Early Recurrence and Patient-Tailored Management. Co-author DOI 10.1245/s10434-024-16810-8↗
  22. Association Between Adjuvant Therapy and Survival in Resected Pancreatic Ductal Adenocarcinoma After Different Types and Durations of Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17439-x↗
  23. ASO Author Reflections: The Impact of Adjuvant Therapy in the Era of Neoadjuvant Strategies for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17788-7↗
  24. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y↗
  25. ASO Author Reflections: Old Truths, New Data: Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Requires Continued Surveillance. First author DOI 10.1245/s10434-025-18007-z↗
  26. The Impact of Social Determinants on Pancreatic Cancer Care in the United States. First author DOI 10.3390/cancers17121898↗
  27. The Impact of Social Determinants of Health on Supportive and Palliative Care in Pancreatic Cancer Management: A Narrative Review. Co-author DOI 10.3390/cancers17193254↗
  28. The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.06.004↗
  29. The Significance of Circulating Tumor Cells in Pancreatic Cancer. Co-author DOI 10.1016/j.yasu.2024.05.001↗
  30. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166↗
  31. Clinical Relevance of Cancerization of Ducts in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002326↗
  32. Progression of Site-specific Recurrence of Pancreatic Cancer and Implications for Treatment. Co-author DOI 10.1097/sla.0000000000006142↗
  33. Total versus Partial Pancreatectomy in Patients with Pancreatic Cancer Arising from Multifocal or Diffuse Intraductal Papillary Mucinous Neoplasia - A Multicen… First author DOI 10.1097/sla.0000000000006538↗
  34. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  35. Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. Co-author DOI 10.1111/jgh.16686↗
  36. Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer. Co-author DOI 10.1136/jitc-2023-008694↗
  37. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  38. Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9-Producing Patients With Pancreati… Co-author DOI 10.1200/po.24.00193↗
  39. Evaluation of AJCC Nodal Staging for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-16055-5↗
  40. ASO Author Reflections: Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: A Need to Evaluate for Specific Staging Systems. Co-author DOI 10.1245/s10434-024-16131-w↗
  41. The value of CA19-9 dynamics in decision making for treatment of locally advanced pancreatic cancer. First author DOI 10.21037/gs-23-477↗
  42. Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer. First author DOI 10.3390/cancers16030489↗
  43. Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification. Co-author DOI 10.1016/j.ejso.2023.04.009↗
  44. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
  45. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000004915↗
  46. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal … Co-author DOI 10.1097/sla.0000000000005710↗
  47. Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. Co-author DOI 10.1245/s10434-022-12901-6↗
  48. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarc… Co-author DOI 10.1001/jamasurg.2022.1362↗
  49. Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mco2.184↗
  50. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-022-06667-x↗

Closest collaborators

The 25 strongest of 180 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ammar A. Javed · 51 shared papers, 2020–2026 · strength 10.89
  2. Christopher Lee Wolfgang · 31 shared papers, 2020–2026 · strength 5.81
  3. Ingmar Florin Rompen · 26 shared papers, 2024–2026 · strength 5.64
  4. Jin Peng He · 27 shared papers, 2020–2026 · strength 4.60
  5. Lois A. Daamen · 22 shared papers, 2023–2026 · strength 4.50
  6. Izaak Quintus Molenaar · 21 shared papers, 2023–2026 · strength 4.08
  7. Christopher L. Wolfgang · 18 shared papers, 2022–2026 · strength 3.92
  8. Greg D. Sacks · 18 shared papers, 2024–2026 · strength 3.82
  9. Benedict Kinny‐Köster · 24 shared papers, 2020–2026 · strength 3.74
  10. Marc G. Besselink · 19 shared papers, 2024–2026 · strength 3.68
  11. Paul C. M. Andel · 17 shared papers, 2024–2026 · strength 3.43
  12. Kelly J. Lafaro · 22 shared papers, 2020–2026 · strength 3.37
  13. Daniel Brock Hewitt · 15 shared papers, 2024–2026 · strength 2.99
  14. Camila Hidalgo Salinas · 11 shared papers, 2025–2026 · strength 2.63
  15. Brady A. Campbell · 12 shared papers, 2024–2026 · strength 2.50
  16. Richard Andrew Burkhart · 17 shared papers, 2020–2026 · strength 2.47
  17. Hjalmar C. van Santvoort · 11 shared papers, 2023–2026 · strength 2.09
  18. William R. Burns · 14 shared papers, 2020–2025 · strength 1.93
  19. Jing He · 7 shared papers, 2023–2026 · strength 1.45
  20. Markus Wolfgang Büchler · 8 shared papers, 2023–2026 · strength 1.41
  21. Martin Loos · 7 shared papers, 2024–2026 · strength 1.24
  22. Alessio Marchetti · 6 shared papers, 2025–2026 · strength 1.20
  23. Sami Shoucair · 8 shared papers, 2021–2025 · strength 1.17
  24. Jun Yu · 9 shared papers, 2019–2023 · strength 1.15
  25. Bas Groot Koerkamp · 6 shared papers, 2024–2026 · strength 1.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.